| Nov 18 |
OS Therapies reports Q3 results
|
| Nov 15 |
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 4 |
OS Therapies to Present at The Spartan Capital Investor Conference
|
| Oct 17 |
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
|
| Sep 13 |
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
|
| Sep 11 |
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
|
| Sep 5 |
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
|
| Aug 29 |
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
|
| Aug 22 |
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
|
| Aug 22 |
OS Therapies Clarifies CUSIP of Common Stock
|
